TRT Aveed denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for trt aveed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Aveed as Duplicate Therapy

Humana's duplicate-therapy denial means their system detected another testosterone replacement agent already active on your claim history — or a recent fill of a different testosterone formulation — and flagged Aveed (testosterone undecanoate long-acting injection) as redundant. This is a coverage logic denial, not a clinical judgment that Aveed won't work for you.

## Why This Denial Is Appealable

Duplicate-therapy flags are frequently wrong or outdated. A prior testosterone formulation may have been discontinued, failed, or caused intolerability — facts that Humana's formulary system cannot see without a clinical review. Aveed's long-acting injectable formulation is pharmacologically distinct from daily gels, patches, or short-acting injections, and your prescriber may have selected it for specific clinical reasons (adherence, absorption variability, or intolerance of other routes). These distinctions must be surfaced in a formal appeal.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial date. Humana must respond within 30 days for non-urgent requests (72 hours for expedited/urgent).
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, you are entitled to an independent external review. For most plans this window is 4 months from the final internal denial. An independent review organization, not Humana, then makes a binding determination.
• Expedited option: If a delay would seriously jeopardize your health, request expedited internal and external review simultaneously.

## Documentation to Gather

1. Diagnosis confirmation — lab results establishing hypogonadism (reference your treating physician's chart; do not rely on single values), clinical symptom documentation. 2. Prior testosterone history — a complete list of every testosterone product previously tried, with start/stop dates, route, reason for discontinuation (failure, side effect, adherence barrier). 3. Formulary/PA history — copies of any prior authorizations or fills Humana is calling "duplicate." 4. Prescriber medical-necessity letter — must explicitly explain why Aveed's specific formulation is necessary and non-duplicative for this patient, with reference to the formulary alternatives that were tried or are contraindicated per the prescribing label and clinical guidelines from the applicable professional society (e.g., the Endocrine Society). 5. Aveed prescribing label — download the current FDA-approved label at DailyMed; it defines the approved indication and REMS requirements your physician is following.

## Criteria-Mapping Structure

Copy each requirement Humana lists in their coverage policy for testosterone therapy into a table. For each requirement, write the exact corresponding fact from the chart (date, value, provider note). Example structure:

| Policy Requirement | Chart Documentation | |---|---| | Prior testosterone product tried | [Agent, dates, reason stopped — from chart] | | Clinical distinction from prior agent | [Prescriber letter explanation] | | Active diagnosis | [Diagnosis code + lab/clinical support] |

Obtain Humana's current medical/coverage policy for testosterone replacement therapy directly from Humana's provider portal or by requesting it in writing — policy numbers and criteria change and must be verified against the version in effect on your denial date.